TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25506933

Group type: EXPERIMENTAL
Intervention: DASH-type healthy diet rich in unsaturated fat (Unsat Fat) for 6 weeks
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: DASH-type healthy diet rich in carbohydrates (Carb) for 6 weeks
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: DASH-type healthy diet rich in protein (Prot) for 6 weeks
Number of subjects: 155
Study: 22397710

Group type: EXPERIMENTAL
Intervention: Elastic band exercise (supervised, 2-3 times a week for 8 weeks)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (conventional modality treatments only)
Number of subjects: 41
Study: 20673678

Group type: EXPERIMENTAL
Intervention: BNP-guided therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Symptom-guided therapy
Number of subjects: 60
Study: 17062658

Group type: EXPERIMENTAL
Intervention: Breathing heliox (35% O2/65% He)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Breathing nitrox (35% O2/65% N2)
Number of subjects: 8
Study: 15668637

Group type: EXPERIMENTAL
Intervention: Postoperative treatment
Number of subjects: 12
Study: 12370681

Group type: EXPERIMENTAL
Intervention: Remifentanil infusion, BIS-titrated
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (sevoflurane concentration varied based on BIS value)
Number of subjects: 40
Study: 10076134

Group type: EXPERIMENTAL
Intervention: Perineal massage
Number of subjects: 1527

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1527
Study: 7478084

Group type: EXPERIMENTAL
Intervention: GnRH Analogues therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GnRH Analogues therapy with Ipriflavone
Number of subjects: 0
Study: 2322634

Group type: EXPERIMENTAL
Intervention: High fat (HF) breakfast
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Low fat (LF) breakfast
Number of subjects: 15

Group type: COMPARATOR
Intervention: Fasted state
Number of subjects: 15
Study: 6112998

Group type: EXPERIMENTAL
Intervention: Gallamine 10 mg
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Gallamine 20 mg
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Tubocurarine 5 mg
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Pancuronium 1 mg
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Fazadinium
Number of subjects: 299
Study: 31999335

Group type: EXPERIMENTAL
Intervention: Systemic antibiotic prophylaxis (SAP) for 2 to 14 days after admission
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Systemic antibiotic prophylaxis (SAP)
Number of subjects: 31
Study: 31786720

Group type: EXPERIMENTAL
Intervention: Patients on ≥ 4 drugs
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Patients at risk of serious or very serious drug interactions
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Correlation between number of drugs taken and risk of serious or very serious interaction
Number of subjects: 188
Study: 27258567

Group type: EXPERIMENTAL
Intervention: Novel triple IHC antibody cocktail (TNP) composed of TTF1, Napsin A, and p40.
Number of subjects: 32

Group type: COMPARATOR
Intervention: Traditional IHC with p63, CK5/6, and TTF1.
Number of subjects: 32
Study: 27699179

Group type: EXPERIMENTAL
Intervention: Medtable™ medication-planning tool
Number of subjects: 674

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 674
Study: 25027101

Group type: EXPERIMENTAL
Intervention: OMEGA‐3 polyunsaturated fatty acids (200 mg/kg/day starting before anesthesia induction for 24 hours followed by 100 mg/kg/day for 7 days)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 21733214

Group type: EXPERIMENTAL
Intervention: OROS methylphenidate (MPH) 18, 36 or 72 mg/day
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: OROS methylphenidate (MPH)
Number of subjects: 370
Study: 20863322

Group type: EXPERIMENTAL
Intervention: Zoster vaccine
Number of subjects: 38546
Study: 18936475

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus interferon alfa (IFN)
Number of subjects: 732

Group type: COMPARATOR
Intervention: Interferon alfa (IFN) monotherapy
Number of subjects: 732
Study: 15753739

Group type: EXPERIMENTAL
Intervention: Intensive insulin treatment
Number of subjects: 79

Group type: COMPARATOR
Intervention: Conventional insulin treatment
Number of subjects: 79
Study: 14518526

Group type: EXPERIMENTAL
Intervention: Acetazolamide (ACZ)
Number of subjects: 11
Study: 10758259

Group type: EXPERIMENTAL
Intervention: Specific behavioral instruments (Cohen‐Mansfield agitation inventory, CERAD behavioral rating scale, revised memory and behavioral problems checklist, agitated behavior in dementia scale)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clinical global impression of change (CGIC)
Number of subjects: 0
Study: 8644655

Group type: EXPERIMENTAL
Intervention: c7E3 bolus and infusion
Number of subjects: 2099

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2099
Study: 1354489

Group type: EXPERIMENTAL
Intervention: Wearing masks during surgery
Number of subjects: 14

Group type: COMPARATOR
Intervention: Not wearing masks during surgery
Number of subjects: 14
Study: 6391391

Group type: EXPERIMENTAL
Intervention: Oral rehydration solution without bicarbonate
Number of subjects: 98

Group type: COMPARATOR
Intervention: World Health Organisation oral rehydration solution (control)
Number of subjects: 98
Study: 31375609

Group type: EXPERIMENTAL
Intervention: Investigated laboratory markers
Number of subjects: 0
Study: 29112461

Group type: EXPERIMENTAL
Intervention: Calcium and Vitamin D supplementation (1250 mg calcium carbonate and 400 IU vitamin D3)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 28290847

Group type: EXPERIMENTAL
Intervention: Akorta
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Crestor
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Crestor-Akorta
Number of subjects: 60

Group type: COMPARATOR
Intervention: Akorta-Crestor
Number of subjects: 60
Study: 25291126

Group type: EXPERIMENTAL
Intervention: Lactobacilli supplementation (L. rhamnosus LR06, L. pentosus LPS01, L. plantarum LP01, L. delbrueckii subsp. delbrueckii LDD01) for 15 days
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (no lactobacilli supplementation)
Number of subjects: 29
Study: 21823209

Group type: EXPERIMENTAL
Intervention: 8 weeks intensive memory training
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 41
Study: 21058198

Group type: EXPERIMENTAL
Intervention: Oral formula with nutrients arginine, RNA, and ω‐3 fatty acids (Group 2)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard enteral formula (Group 1)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Enriched enteral formula (Group 2)
Number of subjects: 40
Study: 17675713

Group type: EXPERIMENTAL
Intervention: Loss frame intervention
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Empowerment frame intervention
Number of subjects: 144

Group type: COMPARATOR
Intervention: Gain frame intervention
Number of subjects: 144
Study: 15660667

Group type: COMPARATOR
Intervention: RGS4 SNPs (1, 4, 7, and 18) in SCZ samples
Number of subjects: 271

Group type: COMPARATOR
Intervention: RGS4 SNPs (1, 4, 7, and 18) in BD samples
Number of subjects: 271
Study: 11898769

Group type: EXPERIMENTAL
Intervention: Low-energy diet with semi-solid meals (2.5 g guar gum)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Low-energy diet with semi-solid meals (without guar gum)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Low-energy diet with solid meals
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Spontaneous meal initiation
Number of subjects: 15
Study: 9448176

Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone (125 mg)
Number of subjects: 255

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 255
Study: 7821106

Group type: EXPERIMENTAL
Intervention: 5 mg isosorbide dinitrate
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 2697886

Group type: EXPERIMENTAL
Intervention: Active treatment with ispaghula husk and propantheline (Group B)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (Group A)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Active treatment after relapse on placebo
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Discontinuation of active treatment
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Reinstitution of active treatment
Number of subjects: 28
Study: 973598

Group type: EXPERIMENTAL
Intervention: Zinfandel wine (9.3% w/v alcohol)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Pure ethanol (9.3% w/v aqueous alcohol solution)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Dealcoholized Zinfandel wine
Number of subjects: 6

Group type: COMPARATOR
Intervention: Deionized water
Number of subjects: 6
Study: 31039320

Group type: EXPERIMENTAL
Intervention: Skim milk (0.1% milk fat)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Whole milk (3.25% milk fat)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Plain Greek yogurt (2% milk fat)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cheddar cheese (31% milk fat)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Water (energy-free control)
Number of subjects: 60
Study: 28611230

Group type: EXPERIMENTAL
Intervention: Motivational interviewing-based health coaching (10 telephone calls over 3 months)
Number of subjects: 50
Study: 25671766

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 1161

Group type: COMPARATOR
Intervention: High C‐Alb levels
Number of subjects: 1161

Group type: COMPARATOR
Intervention: C‐Alb
Number of subjects: 1161
Study: 24117692

Group type: EXPERIMENTAL
Intervention: 10-day sequential therapy (omeprazole and amoxicillin for 5 days followed by omeprazole, clarithromycin and metronidazole for 5 days)
Number of subjects: 360

Group type: COMPARATOR
Intervention: 7-day standard triple therapy (omeprazole, amoxicillin and clarithromycin)
Number of subjects: 360

Group type: COMPARATOR
Intervention: 10-day standard triple therapy (omeprazole, amoxicillin and clarithromycin)
Number of subjects: 360
Study: 16373409

Group type: EXPERIMENTAL
Intervention: HCG group (vaginal progesterone after HCG administration)
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: OR group (vaginal progesterone at the day of oocyte retrieval)
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: ET group (vaginal progesterone at the day of embryo transfer)
Number of subjects: 385
Study: 14626871

Group type: EXPERIMENTAL
Intervention: 2 percent mepivacaine hydrochloride with 1:20,000 levonordefrin
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 3 percent mepivacaine hydrochloride without vasoconstrictor
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Maximum recommended dose of mepivacaine
Number of subjects: 36
Study: 10797161

Group type: EXPERIMENTAL
Intervention: Early hospital discharge and home-based rehabilitation (median duration, 5 weeks)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Usual inpatient rehabilitation and follow-up care
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Home-based rehabilitation
Number of subjects: 86

Group type: COMPARATOR
Intervention: Conventional rehabilitation care
Number of subjects: 86
Study: 8618582

Group type: EXPERIMENTAL
Intervention: 20 mg famotidine twice daily
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: 40 mg famotidine twice daily
Number of subjects: 285

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 285
Study: 1431190

Group type: EXPERIMENTAL
Intervention: Transrectal hyperthermia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3977557

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 49

Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 49
Study: 31779684

Group type: EXPERIMENTAL
Intervention: Video Education Intervention offered every 6 months for 18 months
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Video Education Intervention
Number of subjects: 360

Group type: COMPARATOR
Intervention: Control group (low-adherence nursing homes)
Number of subjects: 360
Study: 28141622

Group type: EXPERIMENTAL
Intervention: Avisetron (8 mg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 26556032

Group type: EXPERIMENTAL
Intervention: Online program plus weekly email prompts
Number of subjects: 0

Group type: COMPARATOR
Intervention: Online program alone
Number of subjects: 0
Study: 24180166

Group type: EXPERIMENTAL
Intervention: Licorice lozenges (Group A)
Number of subjects: 100
Study: 21470071

Group type: EXPERIMENTAL
Intervention: Zaltoprofen (80 mg t.i.d.)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Diclofenac (50 mg t.i.d.)
Number of subjects: 213
Study: 19447425

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (300 mg orally daily)
Number of subjects: 212
Study: 18042533

Group type: EXPERIMENTAL
Intervention: Chicken-based formula
Number of subjects: 38

Group type: COMPARATOR
Intervention: Soy-based formula
Number of subjects: 38

Group type: COMPARATOR
Intervention: Comparison of intolerance rates
Number of subjects: 38
Study: 14706765

Group type: EXPERIMENTAL
Intervention: Low-dose synthetic conjugated estrogens A (SCE-A), 0.3 mg once daily for 16 weeks
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Low-dose synthetic conjugated estrogens A (SCE-A)
Number of subjects: 71
Study: 11405527

Group type: EXPERIMENTAL
Intervention: Proportional Positive Airway Pressure (PPAP)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Preference
Number of subjects: 12
Study: 9928648

Group type: EXPERIMENTAL
Intervention: Histoacryl blue tissue adhesive glue
Number of subjects: 163

Group type: COMPARATOR
Intervention: Sutures
Number of subjects: 163
Study: 7758607

Group type: EXPERIMENTAL
Intervention: Digoxin in combination with diuretics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of digoxin and diuretics with a blocker of the renin‐angiotensin system (kapothenum)
Number of subjects: 0
Study: 3058101

Group type: EXPERIMENTAL
Intervention: 2% MK-927 ophthalmic solution
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 12
Study: 30735466

Group type: COMPARATOR
Intervention: Control arm patients from the DEFUSE 3 trial
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control arm patients with persistent mismatch
Number of subjects: 0
Study: 27810987

Group type: EXPERIMENTAL
Intervention: HbA1c ≥5.7%
Number of subjects: 4095

Group type: COMPARATOR
Intervention: HbA1c, FPG, and 2hPG
Number of subjects: 4095
Study: 25873370

Group type: EXPERIMENTAL
Intervention: Polyphenon E (PolyE) - 400 mg (‐)‐epigallocatechin‐3‐gallate (EGCG) per day
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Polyphenon E (PolyE)
Number of subjects: 97
Study: 23792649

Group type: EXPERIMENTAL
Intervention: Low-dose Tacrolimus QD
Number of subjects: 102

Group type: COMPARATOR
Intervention: Tacrolimus BID
Number of subjects: 102
Study: 21296768

Group type: EXPERIMENTAL
Intervention: Intercostal nerve block plus i.v. patient-controlled analgesia with morphine
Number of subjects: 92

Group type: COMPARATOR
Intervention: Patient-controlled epidural anaesthesia (EDA)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 92
Study: 19795984

Group type: EXPERIMENTAL
Intervention: Immediate treatment with facial fillers (poly‐l‐lactic acid or polyacrylamide gel)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Delayed treatment with facial fillers (poly‐l‐lactic acid or polyacrylamide gel)
Number of subjects: 134
Study: 16492856

Group type: EXPERIMENTAL
Intervention: succinylcholine 1.0 mg/kg
Number of subjects: 160

Group type: COMPARATOR
Intervention: rocuronium 0.6 mg/kg
Number of subjects: 160
Study: 15527609

Group type: EXPERIMENTAL
Intervention: Computerised patient-specific guidelines following case-finding
Number of subjects: 762

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 762
Study: 12563891

Group type: EXPERIMENTAL
Intervention: Intranasal capsaicin (3 x 10(‐6) mol, dissolved in 70% ethanol)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Capsaicin vehicle (70% ethanol)
Number of subjects: 51
Study: 9308617

Group type: EXPERIMENTAL
Intervention: Preoperative optimization of hemodynamic parameters (adjusting hemoglobin concentration, oxygen saturation, cardiac output, or afterload until SvO2 was at least 65%)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Preoperative optimization of hemodynamic parameters
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (placement of PAC without optimization)
Number of subjects: 72
Study: 8154167

Group type: EXPERIMENTAL
Intervention: Coronary bypass-surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Palliative PTCA
Number of subjects: 0
Study: 3532742

Group type: EXPERIMENTAL
Intervention: Intracoronary streptokinase (SK)
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: Intracoronary SK only
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: Intravenous plus intracoronary SK
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: Patent infarct-related coronary artery
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: Successful recanalization during intracoronary SK infusion
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: Persistent coronary occlusion despite thrombolytic therapy
Number of subjects: 533
Study: 29633983

Group type: EXPERIMENTAL
Intervention: Water group (substituted water for DBs)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Water group
Number of subjects: 71
Study: 26886719

Group type: EXPERIMENTAL
Intervention: Thulium laser enucleation of the prostate (ThuLEP)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Plasmakinetic enucleation of the prostate (PKEP)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 127
Study: 24797659

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (n=10)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sedentary control (n=8)
Number of subjects: 18
Study: 22657939

Group type: EXPERIMENTAL
Intervention: CBL module with case-based scenarios
Number of subjects: 124

Group type: COMPARATOR
Intervention: CBL module without case-based scenarios
Number of subjects: 124
Study: 20157654

Group type: EXPERIMENTAL
Intervention: RelyX Unicem (self-adhesive resin cement)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Panavia F2.0 (resin cement with self-etching primer)
Number of subjects: 0
Study: 18414359

Group type: COMPARATOR
Intervention: Desflurane alone (Group A1, n = 27)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Desflurane with 60% nitrous oxide (Group N1, n = 26)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Desflurane alone (Group A3, n = 26)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Desflurane with 60% nitrous oxide (Group N3, n = 24)
Number of subjects: 103
Study: 15849974

Group type: EXPERIMENTAL
Intervention: Drug treatments for acute manic or depressive episodes
Number of subjects: 0
Study: 11818112

Group type: EXPERIMENTAL
Intervention: 15 days of 50 microg/day transdermal 17beta‐estradiol (TE) administration
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 15 days of 100 microg/day transdermal 17beta‐estradiol (Estraderm‐Ciba) administration
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (previous total hysterectomy with intact ovaries)
Number of subjects: 30
Study: 10385059

Group type: EXPERIMENTAL
Intervention: Triple therapy (colloidal bismuth subcitrate, tetracycline, metronidazole) for 2 weeks
Number of subjects: 112

Group type: COMPARATOR
Intervention: Sucralphate (1 g, q.i.d.) for 4 weeks
Number of subjects: 112

Group type: COMPARATOR
Intervention: Ranitidine (150 mg, b.d.) for 4 weeks
Number of subjects: 112
Study: 8678767

Group type: EXPERIMENTAL
Intervention: FDG-PET
Number of subjects: 34

Group type: COMPARATOR
Intervention: Conventional radiological imaging
Number of subjects: 34
Study: 1875423

Group type: EXPERIMENTAL
Intervention: Fundal Height (FH) method
Number of subjects: 100

Group type: COMPARATOR
Intervention: Percentage of Maternal Abdominal Length (PMAL) method
Number of subjects: 100
Study: 6123330

Group type: EXPERIMENTAL
Intervention: 10 mg bunitrolol (BU)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 10 mg methypranol (ME)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 31308556

Group type: EXPERIMENTAL
Intervention: Combination of Intense Pulse Light and topical eflornithine therapy (topical eflornithine applied twice a day and IPL session once a month for 6 months)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Intense Pulse Light therapy alone (IPL monthly sessions for 6 months)
Number of subjects: 78
Study: 28372653

Group type: EXPERIMENTAL
Intervention: 20ml of 0.75% ropivacaine with 1ml (4mg) of perineural dexamethasone (Dpn group, n=20)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 20ml of 0.75% ropivacaine with 1ml of isotonic saline and intravenous 4mg dexamethasone (Div group, n=20)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 20ml of 0.75% ropivacaine with 1ml of isotonic saline (C group, n=20)
Number of subjects: 60
Study: 25312782

Group type: EXPERIMENTAL
Intervention: Transcutaneous continuous carbon dioxide tension (PtcCO2) monitoring
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (blinded to PtcCO2 values)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: PtcCO2 and PaCO2 measurements
Number of subjects: 50
Study: 23525419

Group type: EXPERIMENTAL
Intervention: 1-day IPC (3 cycles of 5' upper-arm ischemia and 5' reperfusion)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 7-day IPC (single daily episodes of IPC for 6 days prior to IR)
Number of subjects: 30

Group type: COMPARATOR
Intervention: IR alone
Number of subjects: 30

Group type: COMPARATOR
Intervention: Celecoxib (cyclooxygenase‐2 inhibitor)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 21489168

Group type: EXPERIMENTAL
Intervention: Standard concentration intranasal fentanyl (SINF)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Highly concentrated intranasal fentanyl (HINF)
Number of subjects: 189
Study: 18024250

Group type: EXPERIMENTAL
Intervention: EMLA
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Lignocaine 1%
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control
Number of subjects: 16
Study: 17230032

Group type: EXPERIMENTAL
Intervention: Escitalopram 10 or 20 mg/day
Number of subjects: 225